"10.1371_journal.pone.0089331","plos one","2014-02-18T00:00:00Z","Walid Nachar; David Busseuil; Yanfen Shi; Teodora Mihalache-Avram; Mélanie Mecteau; Eric Rhéaume; Jean-Claude Tardif","Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada; Department of Medicine, Université de Montréal, Montreal, Quebec, Canada","Conceived and designed the experiments: WN DB ER JCT. Performed the experiments: WN DB YS TMA MM. Analyzed the data: WN DB YS ER JCT. Contributed reagents/materials/analysis tools: JCT. Wrote the paper: WN DB ER JCT.","The authors have the following interests: The following patents on the theme of HDL and both aortic valve stenosis and diastolic dysfunction were submitted by the Montreal Heart Institute and Drs. Tardif, Rhéaume and Busseuil are mentioned as authors. WO/2010/083611A1 Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteinA1 (APOA1) mimetic peptide/phospholipid complex. US20130197226 /Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex. US20090186808 Method and compound for the treatment of valvular disease. These patents do not cover the development of a diastolic dysfunction in a rabbit model, nor the use or selection of housekeeping genes. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","02","Walid Nachar","WN",7,TRUE,4,5,5,4,TRUE,TRUE,FALSE,0,NA,FALSE
